Detail

Chr	chr16
start	69933103
end	69933124
ID	MIMAT0000431
miRNA_name	hsa-miR-140-5p
methods	qRT-PCR,etc
regulated	up
Function Description	Conclusions: ct-miRNAs discriminate patients with and without pCR after neoadjuvant lapatinib- and/or trastuzumab-based therapy. ct-miRNAs at week two could be valuable to identify patients responsive to trastuzumab, to avoid unnecessary combination with other anti-HER2 agents, and finally to assist deescalating treatment strategies.
PMID	30814109
year	2019
Title	Plasma miRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: results from the NeoALTTO trial.
drug	X
circulating	V
survival	X